MiR-29b may suppresses peritoneal metastases through inhibition of the mesothelial-mesenchymal transition (MMT) of human peritoneal mesothelial cells.
Animals
Antigens, CD
/ metabolism
Cadherins
/ metabolism
Calbindin 2
/ metabolism
Cell Adhesion
Cell Line, Tumor
Cell Movement
Cell Proliferation
Coculture Techniques
Epithelial Cells
/ drug effects
Epithelial-Mesenchymal Transition
/ drug effects
Fibronectins
/ metabolism
Humans
Mice, Inbred C57BL
MicroRNAs
/ genetics
Peritoneal Neoplasms
/ genetics
Peritoneum
/ drug effects
Transforming Growth Factor beta1
/ pharmacology
Vimentin
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 01 2022
07 01 2022
Historique:
received:
02
08
2021
accepted:
30
11
2021
entrez:
8
1
2022
pubmed:
9
1
2022
medline:
24
2
2022
Statut:
epublish
Résumé
Peritoneal dissemination is a major metastatic pathway for gastrointestinal and ovarian malignancies. The miR-29b family is downregulated in peritoneal fluids in patients with peritoneal metastases (PM). We examined the effect of miR-29b on mesothelial cells (MC) which play critical a role in the development of PM through mesothelial-mesenchymal transition (MMT). Human peritoneal mesothelial cells (HPMCs) were isolated from surgically resected omental tissue and MMT induced by stimulation with 10 ng/ml TGF-β1. MiR-29b mimics and negative control miR were transfected by lipofection using RNAiMAX and the effects on the MMT evaluated in vitro. HPMC produced substantial amounts of miR-29b which was markedly inhibited by TGF-β1. TGF-β1 stimulation of HPMC induced morphological changes with decreased expression of E-cadherin and calretinin, and increased expression of vimentin and fibronectin. TGF-β1 also enhanced proliferation and migration of HPMC as well as adhesion of tumor cells in a fibronectin dependent manner. However, all events were strongly abrogated by simultaneous transfection of miR-29b. MiR-29b inhibits TGF-β1 induced MMT and replacement of miR-29b in the peritoneal cavity might be effective to prevent development of PM partly through the effects on MC.
Identifiants
pubmed: 34997082
doi: 10.1038/s41598-021-04065-2
pii: 10.1038/s41598-021-04065-2
pmc: PMC8742040
doi:
Substances chimiques
Antigens, CD
0
CALB2 protein, human
0
CDH1 protein, human
0
Cadherins
0
Calbindin 2
0
Fibronectins
0
MIRN29B1 microRNA, human
0
MicroRNAs
0
Transforming Growth Factor beta1
0
VIM protein, human
0
Vimentin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K07704
Informations de copyright
© 2022. The Author(s).
Références
Epigenetics. 2012 Aug;7(8):940-9
pubmed: 22805767
J Clin Invest. 2014 Oct;124(10):4614-28
pubmed: 25202979
Hepatology. 2014 Nov;60(5):1645-58
pubmed: 25048396
Biomed Rep. 2017 Jun;6(6):599-604
pubmed: 28584629
PLoS One. 2014 Feb 04;9(2):e88018
pubmed: 24505356
Int J Cancer. 2020 Apr 15;146(8):2268-2280
pubmed: 31904865
Cancers (Basel). 2020 Feb 21;12(2):
pubmed: 32098058
N Engl J Med. 2003 Jan 30;348(5):403-13
pubmed: 12556543
Cancer Discov. 2011 Jul;1(2):144-57
pubmed: 22303516
Int J Biochem Cell Biol. 2004 Jan;36(1):9-16
pubmed: 14592528
Cancer Metastasis Rev. 2012 Jun;31(1-2):397-414
pubmed: 22527451
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
Oncol Rep. 2020 Apr;43(4):1081-1088
pubmed: 32323853
Ann Gastroenterol Surg. 2019 Nov 06;4(1):84-93
pubmed: 32021962
Nat Cell Biol. 2013 Feb;15(2):201-13
pubmed: 23354167
Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79
pubmed: 17018256
PLoS One. 2015 Apr 15;10(4):e0123926
pubmed: 25874772
J Pathol. 2013 Dec;231(4):517-31
pubmed: 24114721
J Cell Physiol. 2019 Nov;234(11):19280-19297
pubmed: 30950056
Cancers (Basel). 2015 Sep 29;7(4):1994-2011
pubmed: 26426054
J Pathol. 2016 May;239(1):48-59
pubmed: 27071481
J Clin Oncol. 2006 Aug 20;24(24):4011-9
pubmed: 16921055
Blood. 2009 Dec 17;114(26):5331-41
pubmed: 19850741
J Cell Biochem. 2013 Jun;114(6):1336-42
pubmed: 23238947
J Cancer Res Clin Oncol. 1984;108(2):236-8
pubmed: 6470030
Eur J Cancer. 2011 Aug;47(12):1883-9
pubmed: 21514148
Pleura Peritoneum. 2019 Oct 04;4(3):20190007
pubmed: 31667329
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
Mol Vis. 2009 Nov 28;15:2488-97
pubmed: 19956414
Gastric Cancer. 2018 Jan;21(1):55-67
pubmed: 28540637
Surg Oncol. 2014 Jun;23(2):99-106
pubmed: 24721661
Cancer Sci. 2018 May;109(5):1480-1492
pubmed: 29532565
Cancer Res. 2015 Apr 15;75(8):1580-91
pubmed: 25744716
Oncol Lett. 2017 Dec;14(6):6991-6998
pubmed: 29344127
J Surg Oncol. 2010 May 1;101(6):457-64
pubmed: 20401915
Cancer Res. 2015 Apr 1;75(7):1332-44
pubmed: 25634213
Exp Cell Res. 1985 Oct;160(2):499-513
pubmed: 3899694
Biochem Biophys Res Commun. 2013 Apr 26;434(1):143-9
pubmed: 23541945
Clin Immunol Immunopathol. 1995 Oct;77(1):27-32
pubmed: 7554479
Oncol Rep. 2014 Apr;31(4):1509-16
pubmed: 24573597
PLoS One. 2011;6(9):e24568
pubmed: 21931759
J Am Soc Nephrol. 2012 Feb;23(2):252-65
pubmed: 22095944
Adv Med. 2014;2014:473134
pubmed: 26556413
Nat Struct Mol Biol. 2013 Nov;20(11):1325-32
pubmed: 24096364